赛伦生物(688163) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥74,319,211.31, a decrease of 1.22% compared to the same period last year[3] - The total profit for the period was ¥37,052,211.73, reflecting an increase of 1.30% year-over-year[3] - The net profit attributable to shareholders was ¥31,233,921.44, up by 1.94% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥27,908,599.12, which increased by 1.43% compared to the same period last year[3] - The basic earnings per share for the quarter was ¥0.29, with a year-to-date figure of ¥0.59, reflecting a 1.72% increase[4] - Total operating revenue for the first three quarters of 2025 reached RMB 175,138,574.09, a slight increase from RMB 173,291,573.09 in the same period of 2024, representing a growth of approximately 1.06%[17] - Net profit for the first three quarters of 2025 was RMB 64,210,654.81, compared to RMB 62,947,540.75 in 2024, indicating an increase of approximately 2.00%[19] - The company’s total profit for the first three quarters of 2025 was RMB 74,817,469.40, compared to RMB 73,631,451.78 in 2024, reflecting an increase of approximately 1.61%[19] Assets and Liabilities - Total assets at the end of the period were ¥1,161,534,035.34, representing a 3.71% increase from the end of the previous year[4] - The company's total liabilities rose to CNY 36,453,171.78 from CNY 24,533,348.17, reflecting an increase in financial obligations[14] - The total equity attributable to shareholders increased to CNY 1,125,080,863.56 from CNY 1,095,500,608.75, showing growth in shareholder value[14] - The company's accounts receivable increased to CNY 65,179,876.60 from CNY 36,678,957.69, indicating improved sales performance[12] - The fixed assets increased to CNY 114,577,515.78 from CNY 108,979,777.03, suggesting ongoing investment in infrastructure[13] - The company reported a total non-current asset of CNY 244,024,044.52, up from CNY 203,671,011.22, reflecting long-term investment growth[13] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥38,166,287.22, which decreased by 6.89% year-to-date[3] - The company's cash and cash equivalents decreased to CNY 74,948,031.35 from CNY 182,107,137.22, indicating a significant reduction in liquidity[12] - Cash flow from operating activities generated a net amount of RMB 38,166,287.22 in 2025, down from RMB 40,989,386.86 in 2024, a decrease of about 6.93%[21] - Cash flow from investing activities resulted in a net outflow of RMB 110,427,075.57 in 2025, contrasting with a net inflow of RMB 53,086,071.07 in 2024[22] - Cash and cash equivalents at the end of the third quarter of 2025 totaled RMB 74,948,031.35, a decrease from RMB 210,364,165.68 at the end of the same period in 2024[23] Research and Development - Research and development expenses totaled ¥4,402,191.05, accounting for 5.92% of revenue, an increase of 0.91 percentage points[4] - The company incurred research and development expenses of RMB 12,878,600.46 in 2025, down from RMB 16,170,774.43 in 2024, a decrease of about 20.00%[18] Non-Recurring Items - Non-recurring gains and losses for the period amounted to ¥3,325,322.32, with a year-to-date total of ¥7,774,982.99[7] - The company reported other income of RMB 497,430.05 in 2025, significantly lower than RMB 3,549,290.77 in 2024, indicating a decline of approximately 86.00%[18] Inventory and Current Assets - The total current assets slightly increased to CNY 917,509,990.82 compared to CNY 916,362,945.70 in the previous period[12] - The company's inventory decreased to CNY 38,759,460.00 from CNY 43,275,462.94, which may indicate improved inventory management[12] Operating Costs - Total operating costs decreased to RMB 105,193,973.75 in 2025 from RMB 107,900,485.01 in 2024, reflecting a reduction of about 2.52%[18]